BR0316111A - Métodos para diagnosticar rcc e outros tumores sólidos - Google Patents

Métodos para diagnosticar rcc e outros tumores sólidos

Info

Publication number
BR0316111A
BR0316111A BR0316111A BR0316111A BR0316111A BR 0316111 A BR0316111 A BR 0316111A BR 0316111 A BR0316111 A BR 0316111A BR 0316111 A BR0316111 A BR 0316111A BR 0316111 A BR0316111 A BR 0316111A
Authority
BR
Brazil
Prior art keywords
solid tumors
methods
rcc
ccr
genes
Prior art date
Application number
BR0316111A
Other languages
English (en)
Inventor
Natalie Constance Twine
Michael E Burczynski
William L Trepicchio
Andrew Dorner
Jennifer A Stover
Donna K Slonim
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BR0316111A publication Critical patent/BR0316111A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Theoretical Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"MéTODOS PARA DIAGNOSTICAR RCC E OUTROS TUMORES SóLIDOS". Métodos, sistemas e equipamentos para diagnosticar o carcinoma de células renais (RCC) e outros tumores sólidos. Esta invenção identifica numerosos genes doentios que são diferencialmente expressos no sangue periférico de pacientes tendo RCC ou outros tumores sólidos em relação aos seres humanos livres de doença. Estes genes doentios podem ser usados como marcadores substitutos para detectar a presença ou ausência de RCC ou outros tumores sólidos.
BR0316111A 2002-11-21 2003-11-21 Métodos para diagnosticar rcc e outros tumores sólidos BR0316111A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42798202P 2002-11-21 2002-11-21
US45978203P 2003-04-03 2003-04-03
PCT/US2003/037481 WO2004048933A2 (en) 2002-11-21 2003-11-21 Methods for diagnosing rcc and other solid tumors

Publications (1)

Publication Number Publication Date
BR0316111A true BR0316111A (pt) 2005-09-13

Family

ID=32397089

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0316111A BR0316111A (pt) 2002-11-21 2003-11-21 Métodos para diagnosticar rcc e outros tumores sólidos

Country Status (8)

Country Link
US (1) US7611839B2 (pt)
EP (1) EP1588142A4 (pt)
JP (1) JP2006514554A (pt)
AU (1) AU2003298689A1 (pt)
BR (1) BR0316111A (pt)
CA (1) CA2505416A1 (pt)
MX (1) MXPA05005283A (pt)
WO (1) WO2004048933A2 (pt)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040248170A1 (en) * 1999-01-06 2004-12-09 Chondrogene Limited Method for the detection of hyperlipidemia related gene transcripts in blood
US20090215058A1 (en) * 2001-01-24 2009-08-27 Health Discovery Corporation Methods for screening, predicting and monitoring prostate cancer
US20090226915A1 (en) 2001-01-24 2009-09-10 Health Discovery Corporation Methods for Screening, Predicting and Monitoring Prostate Cancer
US20090215024A1 (en) * 2001-01-24 2009-08-27 Health Discovery Corporation Biomarkers upregulated in prostate cancer
US8008012B2 (en) * 2002-01-24 2011-08-30 Health Discovery Corporation Biomarkers downregulated in prostate cancer
AU2003232872A1 (en) 2002-05-27 2003-12-12 Ostergotlands Lans Landsting Method for determining immune system affecting compounds
US8163692B2 (en) * 2002-11-13 2012-04-24 University Of North Texas Health Science Center Of Fort Worth Protection against and treatment of ionizing radiation
US20060182749A1 (en) * 2002-11-13 2006-08-17 Board Of Regents, The University Of Texas System Therapies for cancer using RLIP76
US9895413B2 (en) 2002-11-13 2018-02-20 Board Of Regents, University Of Texas System Protection against and treatment of ionizing radiation
US20050123594A1 (en) * 2002-11-13 2005-06-09 Sanjay Awasthi Liposomes for protection against toxic compounds
CA2505416A1 (en) 2002-11-21 2004-06-10 Wyeth Methods for diagnosing rcc and other solid tumors
WO2004067716A2 (en) 2003-01-24 2004-08-12 Agensys, Inc. Nucleic acids and corresponding proteins entitled 254p1d6b useful in treatment and detection of cancer
US7643943B2 (en) 2003-02-11 2010-01-05 Wyeth Llc Methods for monitoring drug activities in vivo
US20050287532A9 (en) * 2003-02-11 2005-12-29 Burczynski Michael E Methods for monitoring drug activities in vivo
WO2004072265A2 (en) * 2003-02-11 2004-08-26 Wyeth Methods for monitoring drug activities in vivo
WO2004097052A2 (en) * 2003-04-29 2004-11-11 Wyeth Methods for prognosis and treatment of solid tumors
EP1522857A1 (en) 2003-10-09 2005-04-13 Universiteit Maastricht Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
CN1914168A (zh) * 2004-02-04 2007-02-14 公立大学法人横浜市立大学 肽基精氨酸脱亚胺酶4抑制剂
US7991557B2 (en) * 2004-06-19 2011-08-02 Genenews Corporation Computer system and methods for constructing biological classifiers and uses thereof
EP1766043A4 (en) * 2004-06-19 2012-05-30 Genenews Corp COMPUTER SYSTEMS AND METHODS FOR CONSTRUCTING BIOLOGICAL CLASSIFIERS AND USES THEREOF
US7820382B2 (en) * 2004-08-03 2010-10-26 Bauer A Robert Method for the early detection of breast cancer, lung cancer, pancreatic cancer and colon polyps, growths and cancers as well as other gastrointestinal disease conditions and the preoperative and postoperative monitoring of transplanted organs from the donor and in the recipient and their associated conditions related and unrelated to the organ transplantation
US8080373B2 (en) * 2004-08-03 2011-12-20 Bauer Jr A Robert Method for the early detection of pancreatic cancer and other gastrointestinal disease conditions
US20080280282A1 (en) * 2004-08-03 2008-11-13 Bauer Jr A Robert Method for early detection of various cancers and gastrointestinal disease and monitoring of transplanted organs
US20060094018A1 (en) * 2004-08-03 2006-05-04 Bauer A R Jr Discovery and a method for the early detection of pancreatic cancer and other disease conditions
SE0402536D0 (sv) 2004-10-20 2004-10-20 Therim Diagnostica Ab Immunoregulation in cancer, chronic inflammatory and autoimmune diseases
US11105808B2 (en) 2004-11-12 2021-08-31 Health Discovery Corporation Methods for screening, predicting and monitoring prostate cancer
WO2006083986A2 (en) * 2005-02-01 2006-08-10 Government Of The U.S.A, As Represented By The Secretary Department Of Health & Human Services Biomarkers for tissue status
WO2006097388A2 (en) * 2005-02-08 2006-09-21 Innogenetics N.V. Nucleic acid variants in the c1qr1 gene associated with altered innate immunity.
RU2007129864A (ru) * 2005-02-18 2009-03-27 Вайет (Us) Фармакогеномные маркеры для прогнозирования солидных опухолей
EP1875246B1 (en) 2005-04-15 2016-10-05 CanImGuide Therapeutics AB Diagnostic method for detecting cancer by measuring amount of a cytokine like il-6
ES2446250T3 (es) * 2005-05-02 2014-03-06 University Of Southern California Marcadores de metilación del ADN asociados con el fenotipo metilador de islas CpG (CIMP) en el cáncer colorrectal humano
US20100152055A1 (en) 2005-09-02 2010-06-17 Satoko Kozono Composition and method for diagnosing kidney cancer and for predicting prognosis for kidney cancer patient
JPWO2007099852A1 (ja) * 2006-02-23 2009-07-16 国立大学法人金沢大学 固形癌のチロシンキナーゼ阻害剤に対する感受性を検査する方法及び検査キット
WO2008086502A2 (en) * 2007-01-10 2008-07-17 University Of Chicago Molecular marker for clear renal cell carcinoma
WO2008136736A2 (en) 2007-05-08 2008-11-13 Canimguide Therapeutics Ab Immunoregulatory structures from normally occurring proteins
US20110045495A1 (en) 2008-01-17 2011-02-24 Yoshinori Tanaka Composition and method for diagnosis or detection of renal cancer
SG10201704689XA (en) * 2008-01-18 2017-07-28 Harvard College Methods of detecting signatures of disease or conditions in bodily fluids
EP2247311A4 (en) * 2008-02-07 2013-10-23 Terapio Corp COMPOSITIONS FOR RELEASING CARGO SUCH AS MEDICINES, PROTEINS AND / OR MATERIAL GENETIC SUBSTANCES
GB0803464D0 (en) * 2008-02-26 2008-04-02 Medical Res Council Methods and compositions
DE102008031699A1 (de) * 2008-07-04 2010-01-14 Protagen Ag Markersequenzen für Prostataentzündungserkrankungen, Prostatakarzinom und deren Verwendung
WO2010033371A2 (en) * 2008-09-22 2010-03-25 Advpharma, Inc. Molecular markers for lung and colorectal carcinomas
EP2767833A3 (en) * 2008-10-21 2014-12-17 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2010096126A1 (en) * 2008-10-29 2010-08-26 Bg Medicine, Inc. Galectin-3 immunoassay
KR101087617B1 (ko) * 2009-03-19 2011-11-29 한국생명공학연구원 Ｅｎｉｇｍａ―Ｍｄｍ２ 상호작용 및 그 용도
CN102573874A (zh) * 2009-07-24 2012-07-11 泰拉皮奥公司 用于辐射后保护的组合物和方法
CA2771706A1 (en) * 2009-08-25 2011-03-17 Bg Medicine, Inc. Galectin-3 and cardiac resynchronization therapy
WO2011073905A1 (en) * 2009-12-14 2011-06-23 Koninklijke Philips Electronics N.V. Novel tumor markers
MX341866B (es) 2010-01-11 2016-09-06 Genomic Health Inc Metodo para usar expresion genica para determinar la probabilidad de un desenlace clinico de cancer renal.
US9606057B2 (en) 2010-06-01 2017-03-28 Todos Medical Ltd. Biochemical analysis of PBMC
US20110301110A1 (en) * 2010-06-03 2011-12-08 Aucagne Romain TRIM33 (TIF1gamma) AS A NEW DIAGNOSTIC MARKER OF CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)
WO2012153326A1 (en) 2011-05-11 2012-11-15 Todos Medical Ltd. Diagnosis of cancer
JP5872285B2 (ja) * 2011-12-28 2016-03-01 株式会社島津製作所 腎がん血中マーカー
AU2013203713B2 (en) 2012-02-13 2015-07-16 Terapio Corporation RLIP76 as a medical chemical countermeasure
US9493810B2 (en) 2012-06-07 2016-11-15 Pioma, Inc. 5-ALA for detection of brain tumors
NZ629538A (en) * 2012-06-28 2016-10-28 Caldera Health Ltd Targeted rna-seq methods and materials for the diagnosis of prostate cancer
EP3483273A1 (en) * 2012-10-31 2019-05-15 Ionis Pharmaceuticals, Inc. Cancer treatment
WO2014077915A1 (en) * 2012-11-14 2014-05-22 Mayo Foundation For Medical Education And Research Methods and materials for identifying malignant skin lesions
WO2014164365A1 (en) * 2013-03-09 2014-10-09 Harry Stylli Methods of detecting head and neck cancer
EP2965077B1 (en) 2013-03-09 2022-07-13 Harry Stylli Methods of detecting cancer
EP3385717A3 (en) * 2013-03-09 2018-10-24 Harry Stylli Methods of detecting prostate cancer
EP3004870B1 (en) 2013-05-28 2019-01-02 Todos Medical Ltd. Differential diagnosis of benign tumors
EP3004392B1 (en) 2013-05-30 2020-09-30 Genomic Health, Inc. Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer
CA2924335A1 (en) 2013-09-17 2015-03-26 Terapio Corporation Methods of preventing or treating mucositis using rlip76
US9611304B2 (en) * 2014-05-29 2017-04-04 The University Of British Columbia TNNT1 mini-promoters
WO2016025717A1 (en) 2014-08-14 2016-02-18 Mayo Foundation For Medical Education And Research Methods and materials for identifying metastatic malignant skin lesions and treating skin cancer
EP3187878B1 (en) 2014-08-26 2019-07-31 Keio University Anti-cancer agent sensitivity-determining marker
EP3191846A4 (en) 2014-09-11 2018-06-13 Harry Stylli Methods of detecting prostate cancer
EP3067698A1 (en) 2015-03-11 2016-09-14 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Pd-ecgf as biomarker of cancer
US10816538B2 (en) * 2016-01-28 2020-10-27 Siemens Healthcare Diagnostics Inc. Methods and apparatus for detecting an interferent in a specimen
CN108738336B (zh) 2016-01-28 2021-08-10 西门子医疗保健诊断公司 用于多视图表征的方法和装置
MX2018013815A (es) 2016-05-10 2019-07-04 Mayo Found Medical Education & Res Metodos y materiales para estadificar y tratar cancer de piel.
EP3523453A4 (en) * 2016-10-05 2020-08-19 Institute Of Environmental Science And Research Limited RNA SEQUENCES USED TO IDENTIFY AN ORGANIC LIQUID
JP2022505266A (ja) * 2018-10-18 2022-01-14 メディミューン，エルエルシー 癌患者の治療を決定する方法
WO2021030604A1 (en) * 2019-08-14 2021-02-18 University Of Massachusetts Urinary rna signatures in renal cell carcinoma (rcc)
WO2023102519A1 (en) * 2021-12-02 2023-06-08 The Children's Medical Center Corporation Gene therapy in succinic semialdehyde dehydrogenase deficiency (ssadhd)

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4489710A (en) 1981-06-23 1984-12-25 Xoma Corporation Composition and method for transplantation therapy
JP2547714B2 (ja) 1981-10-23 1996-10-23 モルキユラ− バイオシステムズ インコ−ポレテツド オリゴヌクレオチド治療剤及びその製法
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4638045A (en) 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5459039A (en) 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
US5498531A (en) 1993-09-10 1996-03-12 President And Fellows Of Harvard College Intron-mediated recombinant techniques and reagents
GB9517780D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
GB9517779D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
US5840506A (en) 1996-06-05 1998-11-24 Thomas Jefferson University Methods for the diagnosis and prognosis of cancer
US5919638A (en) 1996-10-08 1999-07-06 Abbott Laboratories Reagents and methods useful for detecting prostate tumors
US6303301B1 (en) 1997-01-13 2001-10-16 Affymetrix, Inc. Expression monitoring for gene function identification
US6063028A (en) 1997-03-20 2000-05-16 Luciano; Joanne Sylvia Automated treatment selection method
US6190857B1 (en) * 1997-03-24 2001-02-20 Urocor, Inc. Diagnosis of disease state using MRNA profiles in peripheral leukocytes
US6087098A (en) 1997-04-15 2000-07-11 The Trustees Of Columbia University In The City Of New York Enhanced reverse transcriptase polymerase chain assay to detect MN in patients with renal cell carcinoma
US6420108B2 (en) * 1998-02-09 2002-07-16 Affymetrix, Inc. Computer-aided display for comparative gene expression
AU9319398A (en) 1997-09-19 1999-04-05 Sequitur, Inc. Sense mrna therapy
US20030104371A1 (en) 1997-09-24 2003-06-05 Strom Terry B. Methods of evaluating transplant rejection
FR2771422B1 (fr) 1997-11-21 2001-07-27 Centre Nat Rech Scient Reactifs et methodes pour la detection de genes lies au complexe majeur d'histocompatibilite d'oiseaux d'elevage, tels que le poulet
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
JP3944996B2 (ja) 1998-03-05 2007-07-18 株式会社日立製作所 Ｄｎａプローブアレー
CA2359816C (en) 1999-01-06 2010-08-03 Genenews Inc. Method for the detection of gene transcripts in blood and uses thereof
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
US6647341B1 (en) 1999-04-09 2003-11-11 Whitehead Institute For Biomedical Research Methods for classifying samples and ascertaining previously unknown classes
WO2000063364A2 (en) 1999-04-21 2000-10-26 American Home Products Corporation Methods and compositions for inhibiting the function of polynucleotide sequences
JP2003516124A (ja) 1999-10-15 2003-05-13 ユニバーシティー オブ マサチューセッツ 標的とした遺伝的干渉の手段としてのｒｎａ干渉経路遺伝子
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
AU2001236519A1 (en) 2000-01-24 2001-07-31 Millennium Pharmaceuitcals, Inc. Identification, assessment, prevention, and therapy of prostate cancer
EP1272630A2 (en) 2000-03-16 2003-01-08 Genetica, Inc. Methods and compositions for rna interference
AU2001240375A1 (en) 2000-03-17 2001-10-03 Benitec Australia Limited Genetic silencing
AU2001249622B2 (en) 2000-03-30 2007-06-07 Massachusetts Institute Of Technology RNA sequence-specific mediators of RNA interference
WO2001092513A1 (en) 2000-05-30 2001-12-06 Johnson & Johnson Research Pty Limited METHODS FOR MEDIATING GENE SUPPRESION BY USING FACTORS THAT ENHANCE RNAi
US20020042072A1 (en) 2000-06-26 2002-04-11 Jacobus Van Meel Method for monitoring the effect of cancer therapies
JP2004527209A (ja) 2000-07-21 2004-09-09 ソーントン、マイケル ヒトキナーゼ
AU2001292870A1 (en) 2000-09-21 2002-04-02 Incyte Genomics, Inc. Protein phosphatases
US7198895B2 (en) * 2000-11-14 2007-04-03 Mohanlal Ramon W In vitro cell-based methods for biological validation and pharmacological screening of chemical entities and biologicals
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
DE10057894A1 (de) * 2000-11-22 2002-06-06 Adnagen Gmbh Diagnose-Kit, DNS-Chip sowie Verfahren zur Diagnostik oder Behandlungskontrolle bei Hodenkrebs
MXPA03004577A (es) 2000-11-28 2003-09-04 Wyeth Corp Analisis de expresion de acidos nucleicos y polipeptidos del inhibidor de diferenciacion utiles en diagnostico y tratamiento de cancer de prostata.
WO2002075314A2 (en) 2000-11-30 2002-09-26 Matritech, Inc. Detection and treatment of prostate cancer
US20020132274A1 (en) 2001-01-17 2002-09-19 Nevalainen Marja T. Diagnostic and monitorings methods for cancer
EP1442062A4 (en) 2001-10-18 2005-11-09 Genentech Inc METHOD FOR TREATING CARCINOMA
CA2505416A1 (en) 2002-11-21 2004-06-10 Wyeth Methods for diagnosing rcc and other solid tumors
US20050287532A9 (en) 2003-02-11 2005-12-29 Burczynski Michael E Methods for monitoring drug activities in vivo
US7643943B2 (en) 2003-02-11 2010-01-05 Wyeth Llc Methods for monitoring drug activities in vivo
WO2004072265A2 (en) 2003-02-11 2004-08-26 Wyeth Methods for monitoring drug activities in vivo
WO2004097052A2 (en) 2003-04-29 2004-11-11 Wyeth Methods for prognosis and treatment of solid tumors

Also Published As

Publication number Publication date
EP1588142A4 (en) 2007-10-31
JP2006514554A (ja) 2006-05-11
AU2003298689A1 (en) 2004-06-18
US7611839B2 (en) 2009-11-03
WO2004048933A3 (en) 2005-11-10
US20040110221A1 (en) 2004-06-10
EP1588142A2 (en) 2005-10-26
MXPA05005283A (es) 2005-07-25
CA2505416A1 (en) 2004-06-10
WO2004048933A2 (en) 2004-06-10

Similar Documents

Publication Publication Date Title
BR0316111A (pt) Métodos para diagnosticar rcc e outros tumores sólidos
WO2006089233A3 (en) Methods and systems for diagnosis, prognosis and selection of treatment of leukemia
WO2006081473A8 (en) Methods for diagnosis and prognosis of epithelial cancers
BR0014890B1 (pt) sistema para alinhar dados de tratamento e/ou diagnàstico refrativo.
DE60237531D1 (de) Verfahren zum trennen von seltenen zellen von fluidproben
DE60016467D1 (de) Ct-systeme zur klinischen überprüfung
DE69930666D1 (de) Krebsnachweisverfahren und reagenzien
WO2006060265A3 (en) Methods and systems for prognosis and treatment of solid tumors
WO2001031580A3 (en) Methods and devices for identifying patterns in biological systems
WO2006093507A3 (en) Methods and systems for predicting cancer outcome
EP1099102A4 (en) TRACE DETECTION OF ANALYTES BY ARTIFICIAL OLFAKTOMETRY
DE69933661D1 (de) Genomische sequenz des 5-lipoxygenase-aktivierenden proteins (flap), polymorphische marker und ihre anwendung in der diagnose von asthma
EP2924440A3 (en) Markers associated with arteriovascular events and methods of use thereof
BR0312947A (pt) terapias para insuficiência renal empregando-se interferon-beta
ATE440629T1 (de) Kanüleneinführungssystem
WO2005091203A3 (en) Systems and methods for treating, diagnosing and predicting the occurrence of a medical condition
WO2005085860A3 (en) New proliferation markers in clinical practice and their use for cancer prognosis or diagnosis
BR0110091A (pt) Composições e processos para terapia e diagnóstico de câncer de mama
BRPI0214840B8 (pt) métodos para a detecção de mutações oncogênicas humanas, métodos automatizados para detectar uma mutação e método e ensaio para identificar um ou mais compostos tendo atividade anti-proliferativa
NL1020758A1 (nl) Werkwijze voor computertomografie alsmede computertomografie(CT-)apparaat.
IL155611A0 (en) Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (sclc)
DE50207866D1 (de) Verwendung löslicher cytokeratin-1-fragmente in diagnostik
DE10292329D2 (de) Werkzeuge zur Diagnostik, molekularen Definition und Therapieentwicklung chronischer entzündlicher Gelenkerkrankungen
DE60026150D1 (de) Diagnostika und therapeutika für osteoporose
DE69739317D1 (de) Früher nachweis einer lysosomalen speicher-krankheit

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]